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INTRODUCTION
Although the survival of children with acute lymphoblas-
tic leukemia (ALL) has been dramatically improved, about
20-30% of these patients still relapse requiring more inten-
sified treatment modality such as hematopoietic cell trans-
plantation (HCT) to be cured (1, 2). In addition, certain group
of children with ALL necessitates HCT at early remission
because they have a high rate of relapse (2-5). With current
intensified chemotherapy, 80-85% of children with acute
myeloid leukemia (AML) achieve remission, but the long-
term event free survival (EFS) remains between 35 to 50%
(6-8). In pediatric AML except patients who have Down syn-
drome or acute promyelocytic leukemia, HCT could be per-
formed in first complete remission (CR), especially for patients
with unfavorable features if they have matched relative donors.
HCT using matched relative donor has showed the better
outcome compared to chemotherapy as post-remission ther-
apy in large cohort studies (9, 10).
Although HCT is recognized as potentially curative treat-
ment for acute leukemia as mentioned above, less than one-
third of children have sibling donor (11). HCT from unre-
lated donors could be another option for the treatment of
children with acute leukemia who need HCT for cure but
lack a suitably matched relative. In general, HCT using unre-
lated donor has been associated with a higher graft-versus-
host disease (GVHD) and treatment related mortality (TRM)
(12, 13). With improvement of human-leukocyte antigen
(HLA) typing methods resulting in less severe GVHD, ad-
vances in prophylaxis and treatment of infections and accu-
mulation of experience on unrelated HCT, the outcome of
unrelated donor HCT approaches those of HCT using ma-
tched sibling donor (14-17). Furthermore, the graft-versus-
leukemia (GVL) effects rationalize the use of unrelated donor
in hematologic malignancies with high risk of relapse (18).
This is the report of a single institution’s experience on the
unrelated donor HCT for 56 children with acute leukemia.
We evaluated the outcomes in children with acute leukemia
who received allogeneic HCT using unrelated donor to see
whether the unrelated donor HCT could be an effective treat-
ment to cure children with acute leukemia. We also report
TRM and GVHD and so on.
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Unrelated Hematopoietic Stem Cell Transplantation for Children with
Acute Leukemia: Experience at a Single Institution
We evaluate the outcomes in children with acute leukemia who received allogene-
ic hematopoietic stem cell transplantation (HCT) using unrelated donor. Fifty-six
children in complete remission (CR) received HCT from unrelated donors between
2000 and 2007. Thirty-five had acute myeloid leukemia, and 21 had acute lymphoid
leukemia. Stem cell sources included bone marrow in 38, peripheral blood in 4,
and cord blood (CB) in 14. Four patients died before engraftment and 52 engraft-
ed. Twenty patients developed grade II-IV acute graft-versus-host disease (GVHD)
and 8 developed extensive chronic GVHD. With median follow-up of 39.1 months,
event free survival and overall survival were 60.4% and 67.5%, respectively, at 5 yr.
Events included relapse in 10 and treatment-related mortality (TRM) in 10. The caus-
es of TRM included sepsis in 4, GVHD in 4 (1 acute GVHD and 3 chronic GVHD),
veno-occlusive disease in 1 and fulminant hepatitis in 1. Patients transplanted with
CB had event free survival of 57.1%, comparable to 63.2% for those transplanted
with other than CB. In conclusion, HCT with unrelated donors is effective treatment
modality for children with acute leukemia. In children with acute leukemia candidate
for HCT but lack suitable sibling donor, unrelated HCT may be a possible treatment
option at the adequate time of their disease.
Key Words : Child; Acute Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation; Unrelated Donor
Received : 12 June 2008
Accepted : 4 November 2008Unrelated HCT for Children with Acute Leukemia 905
MATERIALS AND METHODS
Between January 2000 and April 2007, 56 children with
acute leukemia underwent allogeneic HCT from unrelated
donors at the Asan Medical Center. The patients’ medical
records were retrospectively reviewed and were analyzed as
of April 2008. All 56 patients were transplanted in CR. Pa-
tients and donors were typed for HLA-A, -B, and -DRB1
by serological method between 2000 and 2002. High molec-
ular resolution typing was performed for HLA-A, -B, -C
and -DRB1 since 2003. Recipient-donor histocompatibili-
ty was determined by serology for HLA-A, -B, and -DRB1
antigens.
The patients were hospitalized in laminar airflow rooms.
To prevent infection, all patients received prophylactic acy-
clovir and itraconazloe or fluconazole. Granulocyte colony-
stimulating factor (G-CSF) was administered to most pati-
ents. The myeloablative conditioning regimen was admin-
istered, and stem cells were infused through a central venous
catheter on day zero. All patients received prophylactic treat-
ment using cyclosporine with methotrexate or prednisone
to prevent acute GVHD. The day of engraftment was defined
as the first of 3 consecutive days on which the granulocyte
count exceeded 0.5×10
9/L and the last of 7 consecutive days
when the platelet count >20×10
9/L without transfusion
support. Donor engraftment was documented by short-tan-
dem repeat polymerase chain reaction (STR-PCR), which
was usually performed on day 28 after transplantation. Acute
and chronic GVHD were diagnosed and graded according
to standard criteria (13-15). Patients were not considered to
be evaluable for acute GVHD if they died before engraftment
or for chronic GVHD if they died before day 100 after trans-
plantation. 
Overall survival (OS) was defined as the time between
transplantation and death due to any causes. EFS was defined
as the time interval from transplantation to first event, either
relapse or death in complete remission. TRM was defined as
death from any cause other than relapse. The Kaplan-Meier
method was used to summarize estimates of OS and EFS
(16), and outcomes were compared by means of the exact
log-rank test. The Student t test was used to compare the
median age at diagnosis and HCT, the white blood cell count
at diagnosis, and the number of days of engraftment. The
chi-square test was used to compare the incidence of GVHD.
Univariate analysis of prognostic factors was examined by
using the approach of Kaplan and Meier and of Cox regres-
sion for fixed and time-dependent factors, respectively (19).
All factors were considered by using defined discrete cate-
gories. Factors significant in univariate analysis were consid-
ered for inclusion in multivariate Cox regression models. P
values <0.05 were considered as statistically significant. All
statistical analyses were conducted with SPSS software (Sta-
tistical Package for the Social Science, version 12.0, SSPS
Inc, Chicago, IL, U.S.A.).
RESULTS
Characteristics of patients at transplantation
The characteristics of patients are shown in Table 1. Of 56
patients, 35 had AML (29 CR1, 6 CR2), and 21 had ALL
(10 CR1, 7 CR2, 4 CR3). Overall the median age at trans-
plantation was 6.3 yr and 37 were male. Thirty-nine patients
received HCT in CR1, 17 beyond CR1. Of 35 patients with
AML, 10 had t(8;21) of whom 7 were in CR1 and 1 was CR2,
2 had t(15;17) in CR2 and none had inv (16). Of 21 patients
with ALL, 4 had t(9;22), 4 had infant ALL of whom 3 had
11q23 abnormalities, 1 had very high initial white cells over
500,000/μ L, 1 had secondary ALL and 11 had early bone mar-
row relapse. Stem cell sources included bone marrow (BM)
Characteristics AML ALL
No. of patients 35 21
Age (yr) at HCT
Median (range) 6.3 (0.6-15.4) 6.9 (1.2-18.4)
Gender (male:female) 24:11 13:8
Cytogenetics 
t(8;21) 10 0
inv(16) 0 0
t(15;17)* 2 0
Monosomy 7 2 0
Complex (>5 abnormal) 2 0
11q23 abnormalities 1 5
t(12;21) 0 1
t(9;22) 0 4
Normal 5 3
Other abnormalities 11 5
Unknown 2 3
Phase of disease
CR1 29 10
≥CR2 6 11
Stem cell sources
Bone marrow 27 11
Peripheral blood 0 4
Cord blood 8 6
Conditioning regimen
Bu/Cy 26 3
TBI/Cy 0 11
Other
� 97
GVHD prophylaxis
Cyclosporine/methotrexate 27 15
Cyclosporine/prednisone 5 5
Cyclosporine/MMF 3 1
Table 1. Clinical characteristics of patients at the time of trans-
plantation
*, CR2 at transplantation; 
� , Bu/Cy/ATG (3), TBI/Cy/ATG (4), Bu/Flu/ATG
(3), Cy/Flu/ATG (2), TBI/VP16 (1), Bu/Cy/VP16 (1), TBI/Cy/Flu/MMF (1),
Bu/Cy/ATG/VP16 (1).
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; No.,
number; HCT, hematopoietic stem cell transplantation; CR, complete
remission; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradi-
ation; ATG, anti-thymocyte globulin; Flu, fludarabine; GVHD, graft-ver-
sus-host disease; MMF, mycophenolate mofetil.906 J.H. Lee, H.S. Yoon, J.S. Song, et al.
in 38, peripheral blood (PB) in 4, and cord blood (CB) in 14.
All of the 42 patients who underwent HCT with BM or PB
were matched at HLA-A, -B, and -DRB1 antigens. In con-
trast, only two of 14 CB transplantation received grafts that
were matched at HLA-A, -B, and -DRB1 antigens. Busul-
fan containing regimen was the most common conditioning
for AML and total body irradiation (TBI)-based regimen for
ALL. The median infused cell doses were 9.7×10
6 CD34
+
cells/kg for non-CB transplantation and 1.6×10
5 CD34
+
cells/kg for CB transplantation, respectively. The transplan-
tation outcomes are shown in Table 2.
Engraftment
Fifty-two of the 56 patients achieved a sustained granulo-
cyte count greater than 0.5×10
9/L at a median of 16 days
(10-48) post transplantation. Three patients, 2 CB transplan-
tation and 1 non-CB transplantation, died before day 28 with-
out recovery of granulocyte count greater than 0.5×10
9/L.
One patient who received CB transplantation died on day
110 of sepsis with a granulocyte count <0.5×10
9/L. Fifty
of the 56 patients achieved a sustained platelet count greater
than 20×10
9/L at a median of 33 days (16-171) post trans-
plantation. CB transplantation had significantly slower neu-
trophil and platelet engraftment than transplantation using
BM or PB (P=0.002, <0.001, respectively; Fig. 1).
Acute and chronic GVHD
Twenty of 52 evaluable patients developed grades II-IV
acute GVHD. Two had grade IV acute GVHD and all those
died of complications related to GVHD. The cumulative
incidence of acute GVHD grade II-IV in evaluable patients
at day 100 post-transplantation was 40.3%. Both univariate
and multivariate analyses revealed that early engraftment
before 15 days post transplantation was associated with higher
incidence of acute GVHD grade II or above (P=0.004, Table
3). Chronic GVHD was developed in 23 of 49 evaluable
patients including clinically extensive chronic GVHD in 8
Outcomes AML ALL
Median day to engraftment
Neutrophil (range) 16 (10-48) 17 (11-43)
Platelet (range) 33 (20-171) 31 (16-147)
GVHD
Acute (evaluable) (34) (18)
0-1 20 12
2-4 14 6
Chronic (evaluable) (31) (18)
Limited 9 6
Clinical extensive 3 5
Treatment-related mortality 5 5
Relapse 8 2
Table 2. Outcomes after transplantation
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; GVHD,
graft-versus-host disease.
Factors
Incidence of
aGVHD
Patients
Univariate
P value
Multivariate
P value
Disease >0.5
ALL 18 36.2%
AML 34 43.9%
Phase of disease 0.36
CR1/2 49 38.6%
CR3 3 66.7%
Stem cell source 0.3
BM/PB 41 44.0%
CB 11 27.3%
Engraftment <0.001 0.004
≤15 days 22 63.3%
>15 days 30 24.4%
Table 3. Risk factors for acute GVHD (Grade II-IV)
aGVHD, acute graft-versus-host disease; AML, acute myeloid leukemia;
ALL, acute lymphoblastic leukemia; CR, complete remission; BM, bone
marrow; PB, peripheral blood; CB, cord blood.
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
n
e
u
t
r
o
p
h
i
l
 
e
n
g
r
a
f
t
m
e
n
t 1.0
0.8
0.6
0.4
0.2
0.0
0 1 02 03 04 05 06 0
Days after transplantation
CB (n=14)
CB (n=14)
Non-CB (n=42)
Non-CB (n=42)
Fig. 1. Engraftment rate of neutrophils (A) and platelets (B) according to stem cell sources. 
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Treatment-related mortality
Ten patients died of causes not related to recurrent leukemia.
The causes of TRM included sepsis in 4, GVHD in 4 (1 acute
GVHD and 2 chronic GVHD), veno-occlusive disease in 1
and fulminant hepatitis in 1. One patient who had late graft
failure is alive in CR at 2 yr post-transplantation. The Kaplan-
Meier estimates of TRM at 100 days, 1 yr and 2 yr were 3.6%,
15%, and 19.5%, respectively. Both univariate and multi-
variate analyses revealed that phase of disease beyond CR1/2
was associated with higher TRM (P=0.04, Table 4).
Relapse
Eight patients with AML and 2 with ALL relapsed at a
median of 6.4 (2.7-58.2) months post-transplantation. Eight
of 10 patients who relapsed died of progressive disease. One
patient who had extramedullary relapse at 2.8 months post-
transplantation received donor lymphocyte infusion and he
survives 38.4 months post-transplantation in remission. The
estimated relapse rate at 5 yr was 24.9%. Although none of
7 patients who have greater than or equal to grade III acute
GVHD relapsed, acute GVHD over grade II was not associ-
ated with decreased relapse rate (0% vs. 28.6%; P=0.21). 
Overall and event free survival
With a median follow-up of 39.1 months (12.7-101.1),
the estimates of EFS and OS for all patients were 60.4% (ALL
65.9%, AML 58.4%) and 67.5% (ALL 62.9%, AML 69.9%),
respectively (Fig. 2). Patients transplanted with CB had EFS
of 57.1%, which was comparable to 63.2% for those trans-
planted with stem cells other than CB. There was no signif-
icant difference of EFS according to phase of disease, stem
cell sources, and acute or chronic GVHD.
DISCUSSION
Although HCT is a curative therapy for pediatric acute
leukemia including relapsed ALL, ALL with very high risk
of relapse at diagnosis and AML except certain group of pati-
ent who had Down syndrome or acute promyelocytic leu-
kemia, only a limited number of children have a matched
sibling donors (11). The major obstacles for unrelated donor
HCT are high treatment related morbidity or mortality as
well as high incidence of GVHD. Balduzzi et al. (12) report-
ed the Seattle’s experience on unrelated donor bone marrow
transplantation for 88 children mostly with hematologic
malignancies. Acute GVHD developed in more than 80%
of evaluable patients and chronic GVHD in more than 60%.
Twenty-five (28%) of 88 patients died in remission and most
Factors TRM @ 5yr Patients
Univariate
P value
Multivariate
P value
Disease 0.38
ALL 21 26.0%
AML 35 15.6%
Phase of disease 0.003 0.04
CR1/2 52 14.3%
CR3 4 75.0%
Stem cell source 0.17
BM/PB 42 15.8%
CB 14 30.7%
Acute GVHD 0.022 0.09
Grade 0/I 32 3.1%
Grade II-IV 20 28.1%
Table 4. Risk factors for TRM
TRM, treatment-related mortality; ALL, acute lymphoblastic leukemia;
AML, acute myeloid leukemia; CR, complete remission; BM, bone mar-
row; PB, peripheral blood; CB, cord blood; GVHD, graft-versus-host
disease. 
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Fig. 2. Probability of 5 yr event free survival (EFS) (A) and overall survial (OS) (B) according to disease. 
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of the death were due to infections associated with GVHD.
Davies et al. (13) also reported high TRM of 53% in patients
receiving matched marrow and 65% in recipients of mis-
matched marrow. In that study, TRM at day 100 was 36%.
With better supportive care including strategy to infectious
diseases and prophylaxis for GVHD as well as improvement
of HLA typing methods resulting in low graft failure and less
severe GVHD, the survival of unrelated donor HCT approach-
es those of HCT using matched sibling donor. Furthermore,
the GVL effects of unrelated donor HCT can provide a ther-
apeutic advantage in hematologic malignancies with high
risk of relapse after transplantation. In the present study, the
graft failure rate including early death, the incidence of grades
II-IV acute GVHD and extensive chronic GVHD were 7.1%,
40.3%, and 16.3%, respectively, and the TRM at 100 days
was 3.7% which are quite comparable to those of matched
sibling donor transplantation (14, 15). The multivariate anal-
ysis revealed that early engraftment before 15 days post trans-
plantation was associated with higher incidence of acute GV-
HD and phase of disease beyond CR1/2 was associated with
higher TRM.
In childhood ALL, chemotherapy provides excellent out-
come and HCT is not usually indicated in first remission.
But some patients with very high-risk features such as age
less than 12 months at presentation or certain type of cyto-
genetic abnormalities require transplantation in first remis-
sion (3, 4, 20-22). Although HCT using matched sibling
donor had showed uniformly satisfactory survival, the out-
come for unrelated HCT has been variable ranging 40% to
70%. In our study, among 10 patients with ALL who received
unrelated HCT in CR1, only 2 died of complications relat-
ed to transplantation at 0.3 months post-transplantation but
all others are alive in remission with a median follow-up of
29 months. Relapsed ALL is another indication of HCT, espe-
cially for patients with early marrow relapse (23). In this study,
among 11 patients who received HCT at relapse, 2 died of
disease progression, 3 died of causes related to treatment,
and 6 survive in remission with a median follow-up of 29
months. Our study showed that unrelated HCT could be
considered in high-risk or relapsed childhood ALL when they
lack matched sibling donor although our study have some
limitations of small number of patients, short follow-up peri-
od and heterogeneous patients.
While there are some controversies for the best post-remis-
sion treatment for childhood AML, several reports revealed
the therapeutic advantage of HCT compared to chemother-
apy (9). HCT could be performed in first remission, especial-
ly for patients with unfavorable features if the patient has
available matched sibling donor. Given the poor prognosis
in childhood AML when treated with chemotherapy alone,
HCT using alternative donors could be a possible treatment
option for patients who do not have matched sibling donor.
We have a policy to perform HCT in childhood AML with-
out Down syndrome or t(15;17) who achieved CR if they
have any available donor including unrelated source. In our
study the EFS for children who received in CR1 was 59.1%
and for children in CR2 was 50.0%.
Recent studies of HCT using umbilical cord blood report
promising results in childhood acute leukemia (24, 25). We
found that the outcome was comparable in patients receiv-
ing cord blood or stem cells other than cord blood. 
As acute GVHD and TRM are still major obstacles for un-
related donor HCT, the more comprehensive approach and ad-
vance in donor selection, prophylaxis and treatment of GVHD
and supportive care including infections are still required to
improve the outcome in unrelated setting. In addition, To
further clarify the role of unrelated HCT for children with
acute leukemia, prospective nation-wide study including
larger number of patients is warranted.
In conclusion, our study suggests that the unrelated HCT
for children with acute leukemia is an effective treatment
modality, and for the patients who need HCT but lack suit-
able sibling donor, HCT using unrelated donor including
cord blood may be a possible option in the adequate time of
disease.
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